Veru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Veru (NASDAQ:VERU - Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $5.00 price target on the stock.

Veru Stock Performance

Shares of VERU remained flat at $0.74 during trading hours on Tuesday. The stock had a trading volume of 834,911 shares, compared to its average volume of 1,676,215. Veru has a 12-month low of $0.36 and a 12-month high of $1.92. The company has a market capitalization of $108.80 million, a PE ratio of -1.55 and a beta of -0.47. The firm's 50 day simple moving average is $0.82 and its 200 day simple moving average is $0.95.

Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01). Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. The firm had revenue of $3.95 million during the quarter, compared to the consensus estimate of $3.50 million. During the same period in the prior year, the company earned ($0.13) EPS. Analysts expect that Veru will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Veru

Hedge funds and other institutional investors have recently made changes to their positions in the business. Gladstone Institutional Advisory LLC boosted its stake in Veru by 34.2% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company's stock worth $44,000 after purchasing an additional 14,500 shares in the last quarter. SG Americas Securities LLC raised its stake in Veru by 185.9% during the 3rd quarter. SG Americas Securities LLC now owns 66,128 shares of the company's stock worth $51,000 after acquiring an additional 42,997 shares during the period. PVG Asset Management Corp purchased a new position in shares of Veru in the second quarter valued at about $474,000. Perceptive Advisors LLC lifted its holdings in Veru by 26.5% in the 2nd quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company's stock worth $5,942,000 after purchasing an additional 1,478,578 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Veru in the second quarter worth $161,000. Institutional investors own 47.16% of the company's stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.